SCHEMBL5846754

SCHEMBL5846754

O=S(OCl)Oc1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 3/20 0.38
TSHR P16473 1/20 0.38
CA4 P22748 1/20 0.35
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA9 Q16790 1/20 0.33
SRC P12931 1/20 0.33
TDP1 Q9NUW8 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
ALOX15 P16050 1/20 0.32
KCNA3 P22001 1/20 0.32
NSD2 O96028 1/20 0.31
HSP90AA1 P07900 1/20 0.31
HKDC1 Q2TB90 1/20 0.31
TLR9 Q9NR96 1/20 0.31
EPHX2 P34913 1/20 0.31
CA5A P35218 1/20 0.31
CA5B Q9Y2D0 1/20 0.31
CYP2C9 P11712 1/20 0.30
CYP2C19 P33261 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL775482 0.85 LTA4H (0.45) LTA4HTSHRCA4CA1CA2
SCHEMBL29524127 0.80 LTA4H (0.41) LTA4HTSHRCA4CA1CA2
SCHEMBL2836966 0.76 CA4 (0.46) LTA4HTSHRCA4CA1CA2
SCHEMBL5846748 0.75 LTA4H (0.41) LTA4HTSHRCA4CA1CA2
SCHEMBL28098825 0.74 CA4 (0.44) LTA4HTSHRCA4CA1CA2
SCHEMBL27976833 0.73 LTA4H (0.39) LTA4HTSHRCA4CA1CA2
SCHEMBL776256 0.73 FFAR1 (0.41) LTA4HTDP1L3MBTL1ALOX15EPHX2
SCHEMBL3884014 0.73 HTT (0.48) TSHRCA1CA2CA9ACHE
SCHEMBL27448179 0.73 TAAR1 (0.40) LTA4HTSHRCA1CA2CA9
SCHEMBL11082104 0.71 CA1 (0.47) CA1CA2CA9TDP1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0079703-B1 CURING COMPOSITIONS Lingner + Fischer GmbH (DE) 1986-09-10 EP claimed
US-4467079-A UNSATURATED MONOMER, POLYMERIZATION CATALYSTS LINGNER & FISCHER GMBH (DE) 1984-08-21 US claimed
EP-0079703-A1 Curing compositions Lingner + Fischer GmbH (DE) 1983-05-25 EP claimed
CN-119350379-A Triphenylboric acid Process for the preparation of esters 上海若济生物医药科技有限公司 2025-01-24 CN disclosed
US-7022833-B2 Process for the preparation of phosphorothioate triesters AVECIA LIMITED (GB) 2006-04-04 US disclosed
US-7019127-B2 Solution phase synthesis of oligonucleotides AVECIA LIMITED (GB) 2006-03-28 US disclosed
US-20050240015-A1 Solution phase synthesis of oligonucleotides AVECIA LIMITED (GB) 2005-10-27 US disclosed
EP-1272501-B1 PROCESS FOR THE PREPARATION OF PHOSPHOROTHIOATE TRIESTERS AVECIA LTD (GB) 2004-05-06 EP disclosed
EP-1325927-A2 Synthesis of oligonucleotides Avecia Limited (GB) 2003-07-09 EP disclosed
US-20030099981-A1 Process for the preparation of phosphorothioate triesters NITTO DENKO AVECIA, INC. 2003-05-29 US disclosed
EP-1066249-B1 PROCESS FOR THE MANUFACTURE OF CYCLOPROPANECARBONITRILE EASTMAN CHEM CO (US) 2003-05-07 EP disclosed
WO-1997003949-A1 PROCESS FOR THE PREPARATION AND SEPARATION OF CYCLOPROPANECARBONITRILE EASTMAN CHEMICAL COMPANY (US) 1997-02-06 WO disclosed
US-5502234-A FROM CYCLOPROPANECARBOXALDEHYDE AND HYDROXYLAMINE EASTMAN CHEMICAL COMPANY (US) 1996-03-26 US disclosed
EP-0079703-B1 CURING COMPOSITIONS Lingner + Fischer GmbH (DE) 1986-09-10 EP disclosed
US-4467079-A UNSATURATED MONOMER, POLYMERIZATION CATALYSTS LINGNER & FISCHER GMBH (DE) 1984-08-21 US disclosed
EP-0079703-A1 Curing compositions Lingner + Fischer GmbH (DE) 1983-05-25 EP disclosed
US-4259462-A Hardenable composition containing diisopropylbenzene dihydroperoxide DENKI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1981-03-31 US disclosed
US-4174311-A Hardenable composition containing diisopropylbenzene dihydroperoxide DENKI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1979-11-13 US disclosed
US-4069340-A ARYLOXY DIMETHYL IMMONIUM CHLORIDES FROM DIMETHYL FORMAMIDE AND CORRESPONDING ARYL CHLOROFORMATES HOOKER CHEMICALS & PLASTICS CORPORATION (US) 1978-01-17 US disclosed
US-3983178-A Immonium salts and derivatives thereof HOOKER CHEMICALS & PLASTICS CORPORATION (US) 1976-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050240015-A1 Solution phase synthesis of oligonucleotides NUDT1, POLR2E, POLRMT LTA4H 2321/4885TSHR 1672/4885CA4 3062/4885
US-20030099981-A1 Process for the preparation of phosphorothioate triesters OSGEP, NUDT1, PNKP LTA4H 2532/4885TSHR 1257/4885CA4 2960/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.